Ribon Therapeutics rids preclinical work, trims staff to focus on two clinical PARP inhibitors

Ri­bon Ther­a­peu­tics, a biotech look­ing to make next-gen­er­a­tion oral PARP in­hibitors, has end­ed pre­clin­i­cal and plat­form work to fo­cus on two clin­i­cal pro­grams.

“Cuts across the or­ga­ni­za­tion” were made to the ap­prox­i­mate­ly 60-em­ploy­ee biotech, chief busi­ness of­fi­cer Gary Sut­ton con­firmed to End­points News in an email. He de­clined to dis­close the num­ber of em­ploy­ees im­pact­ed by the lay­offs.

“We great­ly ap­pre­ci­ate the con­tri­bu­tions from our team and came to our de­ci­sion af­ter care­ful­ly con­sid­er­ing what was best for our clin­i­cal pro­grams and the pa­tients they could po­ten­tial­ly serve,” Sut­ton said.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Bill Humphries joins MedPharm as CEO

MedPharm offers services for transepithelial and topical products which includes early-phase research and in vitro testing. Credit: Akira AB November8/Shutterstock. MedPharm has appointed Bill Humphries

Read More »